IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Marco-Ayala, Javier
  • Chorao, Pedro
  • Facal, Ana
  • Villalba, Marta

Grupos

Abstract

BACKGROUND: Post-transplant cyclophosphamide (PT-Cy)-based graft-versus-host disease (GVHD) prophylaxis is progressively being used in allogeneic hematopoietic stem cell transplantation (allo-HSCT) from HLA-matched related donors (MRD). However, information regarding the transfusion needs in this setting is lacking. OBJECTIVES: to compare red blood cell (RBC) and platelet units transfused and time to transfusion independence according to the GVHD prophylaxis in MRD HSCT. STUDY DESIGN: We performed a matched-pair analysis comparing the transfusion requirements and the clinical outcomes of patients who received a MRD peripheral blood HSCT using PT-Cy from January 2017 until June 2021 (n = 100) with historical MRD transplants using standard cyclosporine A-based prophylaxis (n = 100). RESULTS: Neutrophil engraftment was significantly delayed in the PT-Cy group as compared with the CsA group (16 days vs. 13 days; P = 0.003). PT-Cy was associated with increased RBC (median, 5 units vs. 4; P = 0.04) and platelet transfusion requirements (median, 6 units vs. 3; P = 0.01) during the first 30 days after transplant. The proportion of patients requiring platelet transfusion during days 31 to 90 after transplant was also higher in the PT-Cy cohort (55% vs. 25%; P < 0.0001). In multivariate analysis, PT-Cy was associated with delayed RBC and platelet transfusion independence ([Hazard ratio [HR] = 0.61; P = 0.007 and HR = 0.51; P < 0.0001, respectively). Cumulative incidence at 100 days of BK polyomavirus (BKPyV)-associated haemorrhagic cystitis grade = 2 was higher in the PT-Cy cohort (34% vs. 12%; P < 0.0001). However, PT-Cy resulted in lower rates of acute GVHD grade II-IV (100-days cumulative incidence 57% vs. 23%; P < 0.0001) and moderate to severe chronic GVHD (1-year cumulative incidence 49% vs. 28%; P = 0.003), as well as improved 2-year overall survival (74% vs. 56%; P = 0.01). CONCLUSIONS: Our study shows that PT-Cy increases transfusion burden in MRD HSCT. However, it results in a low incidence of severe GVHD, with encouraging survival outcomes.

Copyright © 2023. Published by Elsevier Inc.

Datos de la publicación

ISSN/ISSNe:
2666-6375, 2666-6367

Transplantation and Cellular Therapy  ELSEVIER SCIENCE INC

Tipo:
Article
Páginas:
3131-31310
PubMed:
36646324
Enlace a otro recurso:
www.scopus.com

Citas Recibidas en Web of Science: 24

Citas Recibidas en Scopus: 22

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • GVHD prophylaxis; posttransplant cyclophosphamide; transfusion

Compartir